OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 544,307 shares, a decline of 37.6% from the December 15th total of 872,385 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average trading volume of 471,049 shares, the days-to-cover ratio is presently 1.2 days. Based on an average trading volume of 471,049 shares, the days-to-cover ratio is presently 1.2 days. Currently, 5.4% of the company’s stock are sold short.

OSR Stock Performance

OSRH stock traded down $0.03 during mid-day trading on Friday, hitting $0.75. The company had a trading volume of 1,252,668 shares, compared to its average volume of 2,787,571. The firm has a market cap of $19.18 million, a PE ratio of -0.67 and a beta of 1.42. OSR has a 12 month low of $0.45 and a 12 month high of $12.54. The stock’s fifty day moving average price is $0.63 and its two-hundred day moving average price is $0.70.

OSR (NASDAQ:OSRH) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter. The firm had revenue of $0.63 million for the quarter.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the SEC. Institutional investors own 55.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on OSRH shares. Wall Street Zen raised shares of OSR to a “sell” rating in a research report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.